Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Soichiro Yoshida
Institution:
Institute of Science Tokyo
Observed institution:
Institute of Science Tokyo
ORCID:
0000-0003-2757-8083
Observed ORCID:
0000-0003-2757-8083
OpenAlex ID:
A5121903251
Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis
2026
·
Motohiro Fujiwara
, Soichiro Yoshida
, et al.
·
Clinical Genitourinary Cancer
·
3
Quantitative Assessment of Additive Effects of Mirabegron and Solifenacin in Overactive Bladder: Re-analysis of SYNERGY Study
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Urology
·
2
Pharmacologic synergy versus independent action in androgen receptor-axis-targeted agent-docetaxel triplet therapy for metastatic hormone-sensitive prostate cancer: a copula-based analysis
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
2
Quantifying benefit of adding docetaxel to androgen receptor-axis therapy in metastatic hormone-sensitive prostate cancer with Bayesian analysis
2026
·
Wei Chen
, Soichiro Yoshida
, et al.
·
International Urology and Nephrology
Show more works
View as search
Works count:
4
Citation count:
7
H-index:
2
I10-index:
Year
Topic
Type